Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Willem M. Smit"'
Autor:
Camille C.B. Kockerols, Jeroen J.W.M Janssen, Nicole M.A. Blijlevens, Saskia K. Klein, Laura G.M. van Hussen-Daenen, Gwendolyn G.Y. van Gorkom, Willem M. Smit, Peter van Balen, Bart J. Biemond, Marjan J. Cruijsen, Maarten F. Corsten, Peter A.W. te Boekhorst, Harry R. Koene, Geerte L. van Sluis, Jan J. Cornelissen, Peter E. Westerweel
Publikováno v:
Haematologica, Vol 108, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/339bc2e6e77449b99514307759bf809b
Autor:
Wendy Deenik, Jeroen J.W.M. Janssen, Bronno van der Holt, Gregor E.G. Verhoef, Willem M. Smit, Marie José Kersten, Simon M.G.J. Daenen, Leo F. Verdonck, Augustin Ferrant, Anton V.M.B. Schattenberg, Pieter Sonneveld, Marinus van Marwijk Kooy, Shulamit Wittebol, Roelof Willemze, Pierre W. Wijermans, H. Berna Beverloo, Bob Löwenberg, Peter J.M. Valk, Gert J. Ossenkoppele, Jan J. Cornelissen
Publikováno v:
Haematologica, Vol 95, Iss 6 (2010)
Background In order to improve the molecular response rate and prevent resistance to treatment, combination therapy with different dosages of imatinib and cytarabine was studied in newly diagnosed patients with chronic myeloid leukemia in the HOVON-5
Externí odkaz:
https://doaj.org/article/52ff014faa724e5c9930e7aea97fd445
Autor:
Inge G.P. Geelen, Stein-Erik Gullaksen, Mette M. Ilander, Ulla Olssen-Strömberg, Satu Mustjoki, Johan Richter, Nicole M.A. Blijlevens, Willem M. Smit, Bjorn T. Gjertsen, Tobias Gedde-Dahl, Berit Markevärn, Malika M.A. Koppes, Peter E. Westerweel, Henrik Hjorth-Hansen, Jeroen J.W.M. Janssen
Publikováno v:
Annals of Hematology, 102(6), 1395-1408. Springer Verlag
Annals of Hematology, 102, 6, pp. 1395-1408
Geelen, I G P, Gullaksen, S-E, Ilander, M M, Olssen-Strömberg, U, Mustjoki, S, Richter, J, Blijlevens, N M A, Smit, W M, Gjertsen, B T, Gedde-Dahl, T, Markevärn, B, Koppes, M M A, Westerweel, P E, Hjorth-Hansen, H & Janssen, J J W M 2023, ' Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response : clinical and immunological effects ', Annals of Hematology, vol. 102, no. 6, pp. 1395-1408 . https://doi.org/10.1007/s00277-023-05199-1
Annals of Hematology, 102, 6, pp. 1395-1408
Geelen, I G P, Gullaksen, S-E, Ilander, M M, Olssen-Strömberg, U, Mustjoki, S, Richter, J, Blijlevens, N M A, Smit, W M, Gjertsen, B T, Gedde-Dahl, T, Markevärn, B, Koppes, M M A, Westerweel, P E, Hjorth-Hansen, H & Janssen, J J W M 2023, ' Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response : clinical and immunological effects ', Annals of Hematology, vol. 102, no. 6, pp. 1395-1408 . https://doi.org/10.1007/s00277-023-05199-1
In order to improve molecular response for a discontinuation attempt in chronic myeloid leukemia (CML) patients in chronic phase, who had not achieved at least a molecular response IS (MR 4.0) after at least 2 years of imatinib therapy, we prospectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ccc3c9777b8e81ed1a850d02fc25862
https://research.vumc.nl/en/publications/328bbec1-473e-4573-8f5b-d581ac5ae885
https://research.vumc.nl/en/publications/328bbec1-473e-4573-8f5b-d581ac5ae885
Autor:
Christel C. L. M. Boons, Lonneke Timmers, Eleonora L. Swart, Imke H Bartelink, Janneke A. Wilschut, Nicole M. A. Blijlevens, Jacqueline G. Hugtenburg, Jeroen Janssen, Willem M. Smit, N. Harry Hendrikse, Peter E. Westerweel
Publikováno v:
European Journal of Clinical Pharmacology, 76, 9, pp. 1213-1226
European Journal of Clinical Pharmacology, 76, 1213-1226
European Journal of Clinical Pharmacology
Boons, C C L M, Timmers, L, Janssen, J J W M, Westerweel, P E, Blijlevens, N M A, Smit, W M, Bartelink, I H, Wilschut, J A, Swart, E L, Hendrikse, N H & Hugtenburg, J G 2020, ' Response and Adherence to Nilotinib in Daily practice (RAND study) : an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib ', European Journal of Clinical Pharmacology, vol. 76, no. 9, pp. 1213-1226 . https://doi.org/10.1007/s00228-020-02910-3
European Journal of Clinical Pharmacology, 76(9), 1213-1226. Springer Verlag
European Journal of Clinical Pharmacology, 76, 1213-1226
European Journal of Clinical Pharmacology
Boons, C C L M, Timmers, L, Janssen, J J W M, Westerweel, P E, Blijlevens, N M A, Smit, W M, Bartelink, I H, Wilschut, J A, Swart, E L, Hendrikse, N H & Hugtenburg, J G 2020, ' Response and Adherence to Nilotinib in Daily practice (RAND study) : an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib ', European Journal of Clinical Pharmacology, vol. 76, no. 9, pp. 1213-1226 . https://doi.org/10.1007/s00228-020-02910-3
European Journal of Clinical Pharmacology, 76(9), 1213-1226. Springer Verlag
Introduction This comprehensive observational study aimed to gain insight into adherence to nilotinib and the effect of (non)adherence on exposure (Cmin) and treatment outcomes. Methods Chronic myeloid leukemia (CML) patients using nilotinib were fol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::160ab8ab8e4c320a9c1c141a9342ff30
https://hdl.handle.net/2066/225505
https://hdl.handle.net/2066/225505
Autor:
Wendy Deenik, Willem M. Smit, Jeroen Janssen, Noortje Thielen, Gert J. Ossenkoppele, Pieter Sonneveld, Gregor Verhoef, Peter J. M. Valk, J.H. Frederik Falkenburg, Harm Sinnige, Rianne A. H. M. Ammerlaan, Anton Schattenberg, Isabel W. T. Chu, M. Schipperus, Bronno van der Holt, Jan J. Cornelissen, Rien van Marwijk Kooy, Marie José Kersten
Publikováno v:
Annals of Hematology, 92, 8, pp. 1049-56
Thielen, N, van der Holt, B, Verhoef, G E G, Ammerlaan, R A H M, Sonneveld, P, Janssen, J J W M, Deenik, W, Falkenburg, J H F, Kersten, M J, Sinnige, H A M, Schipperus, M, Schattenberg, A, Kooy, R V, Smit, W M, Chu, I W T, Valk, P J M, Ossenkoppele, G J & Cornelissen, J J 2013, ' High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group ', Annals of Hematology, vol. 92, no. 8, pp. 1049-1056 . https://doi.org/10.1007/s00277-013-1730-4
Annals of hematology, 92(8), 1049-1056. Springer Verlag
Annals of Hematology, 92(8), 1049-1056. Springer Verlag
Annals of Hematology, 92(8), 1049-1056
Annals of Hematology, 92, 1049-56
Thielen, N, van der Holt, B, Verhoef, G E G, Ammerlaan, R A H M, Sonneveld, P, Janssen, J J W M, Deenik, W, Falkenburg, J H F, Kersten, M J, Sinnige, H A M, Schipperus, M, Schattenberg, A, Kooy, R V, Smit, W M, Chu, I W T, Valk, P J M, Ossenkoppele, G J & Cornelissen, J J 2013, ' High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group ', Annals of Hematology, vol. 92, no. 8, pp. 1049-1056 . https://doi.org/10.1007/s00277-013-1730-4
Annals of hematology, 92(8), 1049-1056. Springer Verlag
Annals of Hematology, 92(8), 1049-1056. Springer Verlag
Annals of Hematology, 92(8), 1049-1056
Annals of Hematology, 92, 1049-56
Item does not contain fulltext Despite the revolutionary change in the prognosis of chronic myeloid leukemia (CML) patients with the introduction of imatinib, patients with resistant disease still pose a considerable problem. In this multicenter, ran
Autor:
Carolien H. Smorenburg, Annette W.G. van der Velden, Elisabeth G.E. de Vries, Aafke H. Honkoop, Annelies H. Boekhout, Ido P. Kema, Bojana Milojkovic Kerklaan, Agnes J. van der Wouw, Jan H.M. Schellens, Erik van Werkhoven, Peter Nieboer, Caroline M.P.W. Mandigers, Maartje Los, Petronella B. Ottevanger, Lonneke Kessels, Dirk J. van Veldhuisen, Renske Altena, Tineke J. Smilde, Willem M. Smit, Jourik A. Gietema, Jaap de Boer
Publikováno v:
Jama Oncology, 2, 1030-7
Jama Oncology, 2, 8, pp. 1030-7
JAMA oncology, 2(8), 1030-1037. AMER MEDICAL ASSOC
Jama Oncology, 2, 8, pp. 1030-7
JAMA oncology, 2(8), 1030-1037. AMER MEDICAL ASSOC
Item does not contain fulltext IMPORTANCE: This is the first randomized placebo-controlled evaluation of a medical intervention for the prevention of trastuzumab-related cardiotoxic effects. OBJECTIVE: To determine as the primary end point whether an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2711005b972b1ee32911914e7a69418
http://hdl.handle.net/2066/171393
http://hdl.handle.net/2066/171393
Autor:
H. de Graaf, M. Polee, Anna K.L. Reyners, Willem M. Smit, A.N.M. Wymenga, Pax H.B. Willemse, Frans L. G. Erdkamp, M A T M van Vugt, Roy I. Lalisang, L. de Munck, K. Hoekman, Michael Schaapveld, Harry Hollema
Publikováno v:
Annals of Oncology, 23(11), 2896-2902. Oxford University Press
Reyners, A K L, de Munck, L, Erdkamp, F L G, Smit, W M, Hoekman, K, Lalisang, R I, de Graaf, H, Wymenga, A N M, Polee, M, Hollema, H, van Vugt, M A T M, Schaapveld, M & Willemse, P H B 2012, ' A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study ', Annals of Oncology, vol. 23, no. 11, pp. 2896-2902 . https://doi.org/10.1093/annonc/mds107
Reyners, A K L, de Munck, L, Erdkamp, F L G, Smit, W M, Hoekman, K, Lalisang, R I, de Graaf, H, Wymenga, A N M, Polee, M, Hollema, H, van Vugt, M A T M, Schaapveld, M & Willemse, P H B 2012, ' A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study ', Annals of Oncology, vol. 23, no. 11, pp. 2896-2902 . https://doi.org/10.1093/annonc/mds107
In ovarian cancer, cyclooxygenase-2 (COX-2) overexpression is prognostic for poor survival. We investigated the efficacy of celecoxib (C), a selective COX-2 inhibitor, added to docetaxel (Taxotere)/carboplatin (DC) in advanced ovarian cancer.In a pha
Autor:
Gert A. van Deijk, Linda de Munck, Anneke M. Westermann, Willem M. Smit, Geert-Jan Creemers, Carolien P. Schröder, Willemijn Vader, Zoran Erjavec, Pax H.B. Willemse, Aart van Bochove, Hiltje de Graaf, Jacqueline M. Stouthard
Publikováno v:
European journal of cancer (Oxford, England, 47(9), 1355-1362. Elsevier Limited
European Journal of Cancer, 47(9), 1355-1362. ELSEVIER SCI LTD
European Journal of Cancer, 47(9), 1355-1362. ELSEVIER SCI LTD
Background: In anthracycline-pretreated metastatic breast cancer (MBC) patients, it is unknown whether weekly single-agent docetaxel is preferable to 3-weekly docetaxel regarding its toxicity and efficacy profile.Patients and methods: In this multice
Autor:
Jozef Sufliarsky, Wim W. ten Bokkel Huinink, Willem M. Smit, Stan B. Kaye, Hal W. Hirte, Stanislav Spanik, Amit M. Oza, A. Johri, Maria Wagnerova
Publikováno v:
Journal of Clinical Oncology. 27:3097-3103
Purpose To evaluate the safety, maximum tolerated dose (MTD), and pharmacokinetics of patupilone administered once every 3 weeks with proactive standardized diarrhea management in patients with resistant or refractory ovarian, fallopian, or peritonea
Autor:
H. Berna Beverloo, Jan J. Cornelissen, Anton Schattenberg, Hanneke C. Kluin-Nelemans, Jeroen Janssen, Pierre W. Wijermans, Gregor Verhoef, Peter J. M. Valk, Augustin Ferrant, Marie José Kersten, Bob Löwenberg, Pieter Sonneveld, Bronno van der Holt, Willem M. Smit, Gert J. Ossenkoppele, S. Wittebol, Marinus van Marwijk Kooy, Petra H. M. Westveer, Roelof Willemze, Wendy Deenik, Leo F. Verdonck
Publikováno v:
Blood, 111(5), 2581-2588. American Society of Hematology
Blood, 111(5), 2581-2588. AMER SOC HEMATOLOGY
Blood, 111, 5, pp. 2581-2588
Deenik, W, van der Holt, B, Verhoef, GE, Smit, W M, Kersten, M J, Kluin-Nelemans, H C, Verdonck, L F, Ferrant, A, Schattenberg, A V, Janssen, J J W M, Sonneveld, P, van Marwijk, K M, Wittebol, S, Willemze, R, Wijermans, P W, Westveer, PH, Beverloo, HB, van der Valk, P, Lowenberg, B, Ossenkoppele, G J & Cornelissen, J J 2008, ' Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia ', Blood, vol. 111, no. 5, pp. 2581-2588 . https://doi.org/10.1182/blood-2007-08-107482
Blood, 111, 2581-2588
Blood, 111(5), 2581-2588. AMER SOC HEMATOLOGY
Blood, 111, 5, pp. 2581-2588
Deenik, W, van der Holt, B, Verhoef, GE, Smit, W M, Kersten, M J, Kluin-Nelemans, H C, Verdonck, L F, Ferrant, A, Schattenberg, A V, Janssen, J J W M, Sonneveld, P, van Marwijk, K M, Wittebol, S, Willemze, R, Wijermans, P W, Westveer, PH, Beverloo, HB, van der Valk, P, Lowenberg, B, Ossenkoppele, G J & Cornelissen, J J 2008, ' Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia ', Blood, vol. 111, no. 5, pp. 2581-2588 . https://doi.org/10.1182/blood-2007-08-107482
Blood, 111, 2581-2588
Contains fulltext : 70504schattenberg.pdf (Publisher’s version ) (Closed access) The HOVON cooperative study group performed a feasibility study of escalated imatinib and intravenous cytarabine in 165 patients with early chronic-phase chronic myelo